Co-Diagnostics披露CFO离职并由内部财务高管接任

----- form8-k.htm -----
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
September 2, 2026
CO-DIAGNOSTICS,
INC.
(Exact
name of registrant as specified in its charter)
Utah
001-38148
46-2609363
(State
or other jurisdiction
of
incorporation)
(Commission
File Number)
(IRS
Employer
Identification
No. )
2401
S. Foothill Drive
,
Suite D
,
Salt Lake City
Utah
84109
(Address
of principal executive offices) (Zip Code)
(801)
438-1036
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, par value $0.001 per share
CODX
The
Nasdaq
Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
September 2, 2026, Co-Diagnostics, Inc. (the “Company”) and Brian Brown, the Company’s Chief Financial Officer, determined
that Mr. Brown’s last day of employment with the Company would be September 2, 2026 (the “Separation Date”). Mr. Brown
served as the Company’s principal financial officer and principal accounting officer through the Separation Date.
Effective
as of the Separation Date, Daniel Bohrer, the Company’s Executive Vice President of Finance and Accounting, will serve as the Company’s
principal financial officer and principal accounting officer. In connection with such appointment, Mr. Bohrer’s annual salary was
increased from $225,000 to $255,000.
Mr.
Bohrer, age 49, became the Company’s Executive Vice President of Finance and Accounting in September 2026. From September 2021
to September 2026, Mr. Bohrer served as the Company’s Vice President of Finance and Accounting where his duties included overseeing
the Company’s accounting department, directing the preparation of financial statements, footnotes and audit support schedules,
preparing the Company’s annual, quarterly and current reports with the SEC, managing all aspects of the Company’s annual
audit, and administering the Company’s equity compensation plan. From October 2016 through September 2021, Mr. Bohrer served as
the Director of Accounting for Workfront, Inc. (acquired by Adobe, Inc. in 2020), a Utah-based software company providing cloud-based
work and project management software, where he was responsible for internal and external financial accounting and reporting, technical
accounting leadership, equity compensation plan administration, and treasury functions including debt compliance reporting and cash forecasting.
From January 2014 through October 2016, Mr. Bohrer served as an Assurance Senior Manager at EY, where he provided audit services to various
clients in multiple industries. Mr. Bohrer holds a Master of Business Administration and Bachelor of Science in Accounting from Utah
State University and is a licensed CPA in the State of Utah.
Mr.
Bohrer (i) has no family relationship with any director or other executive officer of the Company or any person nominated or chosen by
the Company to become a director or executive officer, (ii) is not a party to any related person transaction with the Company, and (iii)
has no arrangements or understandings with any other person pursuant to which he was selected as an officer of the Company.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
CO-DIAGNOSTICS,
INC.
Date:
September 4, 2026
By:
/s/
Dwight Egan
Name:
Dwight
Egan
Title:
Chief
Executive Officer
(Principal
Executive Officer)